Comparison of anti-HCV seroprevalence of patients who underwent cataract surgery and other ophthalmic procedures

Abstract

Aims: The aim of this study is to evaluate the Anti-HCV seroprevalence in patients who underwent cataract surgery and to compare the prevalence with other ophthalmic surgery procedures. Methods: Patients who underwent ophthalmic surgeries between January 2017 and January 2023 and were preoperatively screened for anti-HCV by ELISA test were included in this study. Patients who underwent cataract surgery formed the study group and other patients were compared as the control group. All data were obtained from the database of the institute and were retrospectively evaluated. Results: A total of 15799 cases were included in the study, and 69.9% had cataracts whereas 30.1% had non-cataract surgery. The mean age of the patients was 63.24±16.04 years. The rate of Anti-HCV seropositive patients was 0.48% (n=53) in the cataract surgery group, and 0.42% (n=20) in those who had non-cataract surgery. However, the difference was not statistically significant (p=0.696). The overall rate of Anti-HCV seropositive cases was %0.46. Conclusion: Even though there was no significant difference between the two groups, the Anti-HCV was positive for almost 1 in 200 ophthalmic procedures. We strongly recommend preoperative screening due to the severity of HCV infection and the risk of surgical transmission.

Keywords

• Cataract
• cataract surgery
• opthalmic surgery
• anti-HCV seroprevalence

References

1. Hashemi H, Pakzad R, Yekta A, et al. Global and regional prevalence of age-related cataract: a comprehensive systematic review and meta-analysis. Eye. 2020;34(8):1357-70.
2. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824.
3. Yoshida K, Nakano H, Yoshitomi F, Oshika T. Prevalence of seropositivity for hepatitis C virus in cataract patients and the general population. J Cataract Refract Surg. 2002;28(10):1789-1792.
4. Steinmetz JD, Bourne RRA, Briant PS; Blindness GBD, Vision Impairment C, Vision Loss Expert Group of the Global Burden of Disease S. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the global burden of disease study. Lancet Glob Health. 2021;9(2):e144-e160.
5. Cicinelli MV, Buchan JC, Nicholson M, Varadaraj V, Khanna RC. Cataracts. Lancet. 2023;401(10374):377-389.
6. Atas M, Karatepe Hashas AS, Demircan S, et al. The investigation of HCV RNA in tear fluid and aqueous humor in patients with anti-HCV antibody positive who underwent cataract surgery. Ocul Immunol Inflamm. 2016;24(3):297-301.
7. Abe T, Nakajima A, Matsunaga M, Sakuragi S, Komatsu M. Decreased tear lactoferrin concentration in patients with chronic hepatitis C. Br J Ophthalmol. 1999;83(6):684-687.
8. Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease. A better indicator than tear mucin. Arch Ophthalmol. 1983;101(8):1284-1287.

9. Çeldir M, Kara I, Coşkuner S, et al. Hepatitis C prevalence in Turkey: estimation through meta-analysis: Ilayda Arjen Kara. Eur J Public Health. 2014;24(suppl_2):cku163-032.
10. Christopher KL, Patnaik JL, Penland KJ, Pantcheva MB, Lynch AM, Ifantides C. Outcomes and risk factors for complications in cataract patients with hepatitis C virus infection. Ophthalmic Epidemiol. 2023;30(5):492-498.
11. Siddiqui E, Naeem S. SP4-17 Prevalence of hepatitis B and C among preoperative cataract patients of Karachi. J Epidemiol Commun Health. 2011;65(Suppl 1):A438-A438.
12. Naeem SS, Siddiqui EU, Kazi AN, Khan S, Abdullah FE, Adhi I. Prevalence of hepatitis ‘B’ and hepatitis ‘C’ among preoperative cataract patients in Karachi. BMC Research Notes. 2012;5(1):1-4.
13. Riaz H, Yasmin S, Kawish AB. Cataract surgery: frequency of Hepatıtıs B & C Vırus infections in patients in Rawalpindi, Pakistan. Professional Med J. 2016;23(08):991-995.
14. Dahab AA, Youssef MM, Eid HM, Elsadi KW. Reporting the undiagnosed cases of hepatitis B and hepatitis C viruses among patients undergoing elective eye surgery in a specialized eye hospital in Egypt. J Ophthalmol. 2019;2019
15. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta‐analysis. Int J Cancer. 2009;124(3):690-697.
16. Kandeel A, Genedy M, El‐Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45-53.
17. Mishra D, Singh H, Gogate P, et al. Prevalence of incidental and total human immunodeficiency virus, hepatitis B and hepatitis C seropositivity among patients posted for cataract surgery at a tertiary care center in India. Indian J Ophthalmol. 2022;70(2):400.
18. WHO . Combating hepatitis B and C to reach elimination to 2030. Geneva: WHO; 2016.
19. Toczylowski K, Bojkiewicz E, Barszcz M, Wozinska-Klepadlo M, Potocka P, Sulik A. Etiology, clinical presentation and incidence of infectious meningitis and encephalitis in Polish children. J Clin Med. 2020;9(8):2324.
20. Cui F, Blach S, Mingiedi CM, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023.8(4):332-342.